Relative efficacy and safety of preservative‐free latanoprost (T2345) for the treatment of open‐angle glaucoma and ocular hypertension. An adjusted indirect comparison meta‐analysis

Abstract Purpose Adjusted indirect comparison (AIC) were performed to assess the relative efficacy and tolerability of T2345 compared to the other prostaglandin analogs for the treatment of open‐angle glaucoma (OAG) and ocular hypertension (OH) Methods We performed a systematic literature review to identify randomized controlled trials evaluating prostaglandin analogs with or without preservative for the treatment of OAG and OH. AIC were conducted using Bucher’s method. The main endpoints was intraocular pressure (IOP) measured at 3 months and hyperhemia or ocular redness Results Twenty‐one studies were included. No statistically significant difference in IOP were found between T2345 and BAK‐free travoprost (mean difference and 95%CI 0.47 [‐0.58;1.51]), bimatoprost (0.49 [‐0.13;1.10]), bimatoprost 0.01% (0.19 [‐0.69;1.06]), travoprost (.27 [‐0.50;1.03]) and latanoprost (0.40 [‐0.02;0.82]). T2345 was found statistically significantly superior to tafluprost (‐0.90 [‐1.52;‐0.28]). For hyperhemia or ocular redness, T2345 was found statistically significantly superior to BAK‐free travoprost (odds ratio 95% CI 0.30 [0.14;0.61]), bimatoprost (0.18 [0.10;0.33]), bimatoprost 0.01% (0.27 [0.13;0.56]), tafluprost (0.18 [0.05;0.65]), travoprost (0.25 [0.14;0.46]) and latanoprost (0.52 [0.31;0.86]) Conclusion In terms of efficacy on IOP, indirect comparisons never found T2345 statistically significantly inferior to the others. T2345 was found superior to tafluprost and an almost statistically significant trend was found in favor of bimatoprost for IOP. For hyperemia or ocular redness, T2345 latanoprost was statistically significantly superior to all the others Commercial interest